| Detailed information |
|---|
| CancerLivER ID | 2025 |
| Biomarker | miR-34a-5p |
| Biomarker Name/Symbol (given in Publication) | miR-34a-5p |
| Biomolecule | miRNA |
| Subject | Sprague- Dawley rats |
| Degree of Validity | TAA-induced hepatocarcinogenesis |
| Experimental Condition | Control Sprague-Dawley rats and rats treated with TAA at three doses; can predict early HCC |
| Cancer type | TAA-induced liver carcinogenesis. |
| Regulation | Upregulated in TAA-induced hepatocarcinogenesis (with Log fold change more than 1.5 to 4.7) |
| Level of significance | p < 0.05 |
| Source | Tissue |
| PMID | 28596526 |
| Type of Biomarker | Potential Diagnostic and Prognostic * |
| Pathway | p53-, TGF-β-, MAPK- and Wnt-signaling |
| Cohort | 48 samples |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | TAA-induced liver carcinogenesis. |
| Year of Publication | 2017 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |